Authors :
Dian Ayu Juwita; Resty Mulyani
Volume/Issue :
Volume 8 - 2023, Issue 4 - April
Google Scholar :
https://bit.ly/3TmGbDi
Scribd :
https://bit.ly/3LPIhcT
DOI :
https://doi.org/10.5281/zenodo.7889079
Abstract :
Type 2 diabetes mellitus is a disease caused by
disturbances in the metabolism of carbohydrates,
proteins, and fats, characterized by hyperglycemia. This
disease is one of the risk factors for chronic kidney
disease, which can affect life expectancy. This study aims
to determine the pattern of antidiabetic drug use and the
rationality of drug use, as well as its relationship with the
patient's discharge condition. This retrospective study
collected medical record data of type 2 diabetes mellitus
patients with chronic kidney disease in 2018. The study
found that 61 patients met the inclusion criteria. Based on
sociodemographic characteristics, the majority of patients
were female (68.9%), aged 46-55 years (36.1%), had
completed high school education (47.5%), and were
housewives (57.4%). The pattern of antidiabetic drug use
in type 2 diabetes mellitus patients with chronic kidney
disease was as follows: 13.11% of patients used
novorapid, 11.47% used lantus, 11.47% used gliclazide,
1.63% used glimepiride, 37.7% used a combination of
novorapid with levemir, 3.27% used a combination of
novorapid with lantus, 3.27% used a combination of
novorapid with gliclazide, 6.55% used a combination of
lantus with apidra, 1.63% used a combination of levemir
with gliclazide, and 9.83% used intravenous critical
insulin drip. The rationality of drug use was 100%
appropriate indication, 95.08% appropriate drug
selection, 100% appropriate patient, 100% appropriate
dose, 100% appropriate frequency, and 100%
appropriate administration route. The chi-square test and
Kruskal-Wallis test showed a p-value >0.05, indicating no
significant relationship between sociodemographic
characteristics and patient discharge condition, as well as
no significant relationship between the rationality of
antidiabetic drug use and patient discharge condition.
Keywords :
Chronic Kidney Disease, Antidiabetic Drug, Rational, CKD, Type 2 Diabetes Mellitus
Type 2 diabetes mellitus is a disease caused by
disturbances in the metabolism of carbohydrates,
proteins, and fats, characterized by hyperglycemia. This
disease is one of the risk factors for chronic kidney
disease, which can affect life expectancy. This study aims
to determine the pattern of antidiabetic drug use and the
rationality of drug use, as well as its relationship with the
patient's discharge condition. This retrospective study
collected medical record data of type 2 diabetes mellitus
patients with chronic kidney disease in 2018. The study
found that 61 patients met the inclusion criteria. Based on
sociodemographic characteristics, the majority of patients
were female (68.9%), aged 46-55 years (36.1%), had
completed high school education (47.5%), and were
housewives (57.4%). The pattern of antidiabetic drug use
in type 2 diabetes mellitus patients with chronic kidney
disease was as follows: 13.11% of patients used
novorapid, 11.47% used lantus, 11.47% used gliclazide,
1.63% used glimepiride, 37.7% used a combination of
novorapid with levemir, 3.27% used a combination of
novorapid with lantus, 3.27% used a combination of
novorapid with gliclazide, 6.55% used a combination of
lantus with apidra, 1.63% used a combination of levemir
with gliclazide, and 9.83% used intravenous critical
insulin drip. The rationality of drug use was 100%
appropriate indication, 95.08% appropriate drug
selection, 100% appropriate patient, 100% appropriate
dose, 100% appropriate frequency, and 100%
appropriate administration route. The chi-square test and
Kruskal-Wallis test showed a p-value >0.05, indicating no
significant relationship between sociodemographic
characteristics and patient discharge condition, as well as
no significant relationship between the rationality of
antidiabetic drug use and patient discharge condition.
Keywords :
Chronic Kidney Disease, Antidiabetic Drug, Rational, CKD, Type 2 Diabetes Mellitus
